BioCryst Pharmaceuticals Inc. (BCRX)

1.79
0.21 13.00
NASDAQ : Health Technology
Prev Close 1.58
Open 1.70
Day Low/High 1.60 / 1.82
52 Wk Low/High 1.38 / 9.95
Volume 3.83M
Avg Volume 1.51M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 197.68M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioCryst Prices Public Offering Of Common Stock

BioCryst Prices Public Offering Of Common Stock

RESEARCH TRIANGLE PARK, N.C.

BioCryst Commences Public Offering Of Common Stock

BioCryst Commences Public Offering Of Common Stock

RESEARCH TRIANGLE PARK, N.C.

BioCryst Reports Third Quarter 2019 Financial Results And Upcoming Key Milestones

BioCryst Reports Third Quarter 2019 Financial Results And Upcoming Key Milestones

—New drug application for oral, once-daily BCX7353 for prevention of hereditary angioedema attacks on-track for submission to FDA in Q4 2019— —Data from proof of concept study in PNH patients with oral Factor D inhibitor, BCX9930, expected in 1H 2020—...

New Clinical Trial Results And Market Research Support Significant Commercial Opportunity For Oral, Once Daily BCX7353 In HAE

New Clinical Trial Results And Market Research Support Significant Commercial Opportunity For Oral, Once Daily BCX7353 In HAE

—Results of the APeX-S and APeX-2 trials show patients taking 150 mg of oral, once daily BCX7353 achieved a stable average attack rate of ≤ 1 attack per month at 48 weeks— —75 percent of patients taking 150 mg BCX7353 completed 48 weeks of dosing in the...

BioCryst Announces Partnership With Torii Pharmaceutical To Commercialize BCX7353 In Japan For The Prevention Of HAE Attacks       

BioCryst Announces Partnership With Torii Pharmaceutical To Commercialize BCX7353 In Japan For The Prevention Of HAE Attacks       

—Agreement includes up to $42 million of upfront and potential milestone payments plus royalties on net sales— —JNDA submission to PMDA on track for Q1 2020— —Deal leverages Torii's proven track record to deliver innovative therapies to Japanese patients—...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C.

BioCryst Begins Phase 1 Trial With BCX9250, An Oral ALK-2 Inhibitor, For Treatment Of Fibrodysplasia Ossificans Progressiva

BioCryst Begins Phase 1 Trial With BCX9250, An Oral ALK-2 Inhibitor, For Treatment Of Fibrodysplasia Ossificans Progressiva

—BCX9250 significantly suppressed heterotrophic ossification in preclinical studies— —Urgent medical need with no approved treatments for FOP — —Phase 1 data expected in 2H 2020— RESEARCH TRIANGLE PARK, N.

BioCryst Reports Data From Phase 1 Trial Of BCX9930 And Announces Plans To Advance Program Into Proof Of Concept Study In PNH Patients

BioCryst Reports Data From Phase 1 Trial Of BCX9930 And Announces Plans To Advance Program Into Proof Of Concept Study In PNH Patients

—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and part 2 MAD data support advancement of program into part 3...

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C.

U.S. Government Exercises Option For Additonal Rapivab® For Strategic National Stockpile

U.S. Government Exercises Option For Additonal Rapivab® For Strategic National Stockpile

$14 million in non-dilutive capital added by year end

BioCryst Pharmaceuticals To Present At Cantor Global Healthcare Conference

BioCryst Pharmaceuticals To Present At Cantor Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C.

BioCryst Appoints Helen Thackray, M.D., To Board Of Directors

BioCryst Appoints Helen Thackray, M.D., To Board Of Directors

RESEARCH TRIANGLE PARK, N.C.

January 2020 Options Now Available For BioCryst Pharmaceuticals (BCRX)

January 2020 Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals Inc saw new options begin trading today, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 127 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C.

BioCryst To Present At H.C. Wainwright Global Investment Conference

BioCryst To Present At H.C. Wainwright Global Investment Conference

RESEARCH TRIANGLE PARK, N.C.

BioCryst Reports Second Quarter 2019 Financial Results

BioCryst Reports Second Quarter 2019 Financial Results

  —New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral Factor D inhibitor, BCX9930, expected in Q4 2019— RESEARCH TRIANGLE PARK, N.

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C.

BioCryst To Report Second Quarter 2019 Financial Results On August 6

BioCryst To Report Second Quarter 2019 Financial Results On August 6

RESEARCH TRIANGLE PARK, N.C.

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C.

Notable Tuesday Option Activity: BCRX, AVYA, WSM

Notable Tuesday Option Activity: BCRX, AVYA, WSM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioCryst Pharmaceuticals Inc , where a total of 25,190 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to about 273.3% of BCRX's average daily trading volume over the past month of 921,645 shares.

Noteworthy Wednesday Option Activity: BCRX, DO, BMI

Noteworthy Wednesday Option Activity: BCRX, DO, BMI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in BioCryst Pharmaceuticals Inc , where a total volume of 15,754 contracts has been traded thus far today, a contract volume which is representative of approximately 1.6 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 156.7% of BCRX's average daily trading volume over the past month, of 1.0 million shares.

BioCryst Pharmaceuticals Breaks Below 200-Day Moving Average - Notable For BCRX

BioCryst Pharmaceuticals Breaks Below 200-Day Moving Average - Notable For BCRX

In trading on Wednesday, shares of BioCryst Pharmaceuticals Inc crossed below their 200 day moving average of $7.72, changing hands as low as $7.45 per share. BioCryst Pharmaceuticals Inc shares are currently trading off about 7.8% on the day.

BCRX May 17th Options Begin Trading

BCRX May 17th Options Begin Trading

Investors in BioCryst Pharmaceuticals Inc saw new options become available today, for the May 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 81 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

July 19th Options Now Available For BioCryst Pharmaceuticals (BCRX)

July 19th Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals Inc saw new options become available today, for the July 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 189 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

BioCryst Pharmaceuticals Reaches Analyst Target Price

BioCryst Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of BioCryst Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $6.60, changing hands for $7.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BioCryst Provides Update On Strategy, Pipeline And Outlook

BioCryst Provides Update On Strategy, Pipeline And Outlook

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company"), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company's strategic and financial...

TheStreet Quant Rating: D- (Sell)